What is Gliosarcoma Market?
Gliosarcoma is a rare type of primary central nervous system (CNS) tumor that begins in the brain or spinal cord. Gliosarcoma is a glioma. These tumors are classified as Grade IV tumors. It is a variant of glioblastoma (along with epithelioid glioblastoma and giant cell glioblastoma) recognized in the WHO classification of CNS tumors. The symptoms may involve headaches, weakness, seizures, thinking or memory difficulties, numbness, or problems with balance and movement.
The market study is being classified by Type (Primary Gliosarcoma and Secondary Gliosarcoma) and major geographies with country level break-up.
Roche Holding AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (United States), Merck & Co., Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (United States), Teva Pharmaceutical Industries Ltd (Israel), Genentech, Inc. (United States), Cadila Healthcare Limited (India) and Intas Biopharmaceuticals (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Edge Pharma Pvt. (India) and Pfizer Inc. (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gliosarcoma market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Gliosarcoma market by Type, Application and Region.
On the basis of geography, the market of Gliosarcoma has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Patients with Gliosarcoma
- Increasing Number of Diagnostic Centres
- Increasing Healthcare Expenditure Across Emerging Markets
- Increasing Number of Research Activities in the Medical Field
- Limited Patient Awareness Related to Disease Diagnosis
- Dearth of Skilled and Well-Trained Professionals
- Growing Target Patient Population
- Continuous Product Development and Commercialization
- Growth in the Healthcare Industry
- Stringent Regulatory Scenario
In February 2019, Roche and Spark Therapeutics, Inc. has announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics. The merger agreement has been unanimously approved by the boards of Spark Therapeutics and Roche.
Key Target AudienceGliosarcoma Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase